AbbVie Published Results of Rinvoq (upadacitinib) & Skyrizi (risankizumab) in Multiple P-III Induction and Maintenance Studies for UC & CD in The Lancet
Shots:
- The P-III (U-ACHIEVE)/(U-ACCOMPLISH) and (U-ACHIEVE) evaluating the safety & efficacy of upadacitinib (45mg, qd as induction therapy) & 15/30mg, qd as maintenance therapy vs PBO in patients with active UC
- The P-III (ADVANCE), (MOTIVATE) and (FORTIFY) study evaluated risankizumab (600/1200mg as induction therapy) & 180/360 mg as maintenance therapy vs PBO in patients with active CD. In both trials, patients had an inadequate response, lost response, or were intolerant to conventional or biological therapy
- In induction & maintenance Studies, the patients treated with upadacitinib achieved an improvement in clinical remission & endoscopic response @8 & 52wks. while on risankizumab @12 & 52wks.
Ref: AbbVie | Image: AbbVie
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
